F9

Summary

Gene Symbol: F9
Description: coagulation factor IX
Alias: FIX, HEMB, P19, PTC, THPH8, Christmas factor, F9 p22, FIX F9, factor 9, factor IX F9, plasma thromboplastic component, plasma thromboplastin component
Species: human

Top Publications

  1. ncbi Nucleotide sequence of the gene for human factor IX (antihemophilic factor B)
    S Yoshitake
    Biochemistry 24:3736-50. 1985
  2. ncbi An age-related homeostasis mechanism is essential for spontaneous amelioration of hemophilia B Leyden
    Sumiko Kurachi
    Age Dimension Research Center, National Institute of Advanced Industrial Science and Technology, Tsukuba, 305 8566 Japan
    Proc Natl Acad Sci U S A 106:7921-6. 2009
  3. ncbi Protein engineering of the propeptide of human factor IX
    P A Handford
    Sir William Dunn School of Pathology, University of Oxford, UK
    Protein Eng 4:319-23. 1991
  4. ncbi [Venous thromboembolic pathology. New acquired risk factors or new data on acquired risk factors]
    L Drouet
    , , , 75010 Paris
    Arch Mal Coeur Vaiss 94:1318-26. 2001
  5. ncbi Zn(2+)-selective purification of recombinant proteins from the milk of transgenic animals
    A Degener
    Department of Chemical Engineering, Virginia Polytechnic Institute and State University, Blacksburg, USA
    J Chromatogr A 799:125-37. 1998
  6. ncbi High-performance capillary electrophoresis for in-process control in the production of antithrombin III and human clotting factor IX
    A Buchacher
    Octapharma Pharmazeutika Produktionsges.m.H, Vienna, Austria
    J Chromatogr A 802:355-66. 1998
  7. ncbi Production of highly purified clotting factor IX by a combination of different chromatographic methods
    L Hoffer
    Octapharma Pharmazeutika Produktionsges, Vienna, Austria
    J Chromatogr A 844:119-28. 1999
  8. ncbi Application of monoliths for downstream processing of clotting factor IX
    K Branovic
    Institute of Immunology, Zagreb, Croatia
    J Chromatogr A 903:21-32. 2000
  9. ncbi [The best in 2000 on angiology]
    J Emmerich
    , , 75908 Paris
    Arch Mal Coeur Vaiss 94:77-81. 2001
  10. ncbi A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone
    K Tomokiyo
    The Chemo Sero Therapeutic Research Institute, Kaketsuken, Okubo, Kumamoto, Japan
    Vox Sang 85:290-9. 2003

Research Grants

  1. Regulation of factor VIII Levels and Activity by Members of LDL Receptor Family
    Dudley Strickland; Fiscal Year: 2009
  2. Regulation of factor VIII Levels and Activity by Members of LDL Receptor Family
    DUDLEY K contact STRICKLAND; Fiscal Year: 2010
  3. BIOCHEMISTRY OF VARIANTS OF FACTOR IX
    S Bajaj; Fiscal Year: 1990
  4. Immunology of Factor IX Gene Transfer to Liver
    Roland W Herzog; Fiscal Year: 2010
  5. Immunology of Factor IX Gene Transfer to Liver
    Roland W Herzog; Fiscal Year: 2011
  6. Bioencapsulated Factor IX for Oral Tolerance in Hemophilia B
    ROLAND HERZOG; Fiscal Year: 2007
  7. GENE THERAPY FOR HEMOPHILIA A AND B
    Inder Verma; Fiscal Year: 2003
  8. Efficacy and Safety of AAV Gene Transfer for Hemophilia
    VALDER ARRUDA; Fiscal Year: 2004
  9. GENE THERAPY FOR BLOOD PROTEIN DEFICIENCIES
    KATHERINE PONDER; Fiscal Year: 2005
  10. Immunology of Factor IX Gene Transfer to Liver
    ROLAND HERZOG; Fiscal Year: 2006

Detail Information

Publications200 found, 100 shown here

  1. ncbi Nucleotide sequence of the gene for human factor IX (antihemophilic factor B)
    S Yoshitake
    Biochemistry 24:3736-50. 1985
    ....
  2. ncbi An age-related homeostasis mechanism is essential for spontaneous amelioration of hemophilia B Leyden
    Sumiko Kurachi
    Age Dimension Research Center, National Institute of Advanced Industrial Science and Technology, Tsukuba, 305 8566 Japan
    Proc Natl Acad Sci U S A 106:7921-6. 2009
    ..This study demonstrates the clinical relevance of the first discovered puberty-onset gene switch, the ASE/AIE-mediated regulatory mechanism...
  3. ncbi Protein engineering of the propeptide of human factor IX
    P A Handford
    Sir William Dunn School of Pathology, University of Oxford, UK
    Protein Eng 4:319-23. 1991
    ..These data support the current hypothesis that the propeptide contains two recognition elements: one for carboxylase recognition located towards the N-terminus, and one for propeptidase recognition located near the C-terminus...
  4. ncbi [Venous thromboembolic pathology. New acquired risk factors or new data on acquired risk factors]
    L Drouet
    , , , 75010 Paris
    Arch Mal Coeur Vaiss 94:1318-26. 2001
    ..If the acquired risk is identified and quantified for a patient, it allows evaluation of global risk and the installation of appropriate therapeutic measures...
  5. ncbi Zn(2+)-selective purification of recombinant proteins from the milk of transgenic animals
    A Degener
    Department of Chemical Engineering, Virginia Polytechnic Institute and State University, Blacksburg, USA
    J Chromatogr A 799:125-37. 1998
    ..Due to the homology of milk proteins among different species, this same Zn(2+)-selective precipitation strategy is useful for developing purification methods for other recombinant proteins from the milk of transgenic livestock...
  6. ncbi High-performance capillary electrophoresis for in-process control in the production of antithrombin III and human clotting factor IX
    A Buchacher
    Octapharma Pharmazeutika Produktionsges.m.H, Vienna, Austria
    J Chromatogr A 802:355-66. 1998
    Antithrombin III (ATIII) and factor IX (FIX), two proteins from the clotting cascade, were investigated in parallel experiments, using capillary gel electrophoresis and capillary isoelectric focusing...
  7. ncbi Production of highly purified clotting factor IX by a combination of different chromatographic methods
    L Hoffer
    Octapharma Pharmazeutika Produktionsges, Vienna, Austria
    J Chromatogr A 844:119-28. 1999
    ..This cuts the period of time required for the process by almost 50%, and increases the yield considerably. The isolated factor IX contains practically no contaminants and has a specific activity over 200 IU/mg of protein...
  8. ncbi Application of monoliths for downstream processing of clotting factor IX
    K Branovic
    Institute of Immunology, Zagreb, Croatia
    J Chromatogr A 903:21-32. 2000
    ..Besides, the same application on the up-scaled tube-shaped monolithic column was successfully carried out...
  9. ncbi [The best in 2000 on angiology]
    J Emmerich
    , , 75908 Paris
    Arch Mal Coeur Vaiss 94:77-81. 2001
    ..Finally, some recent data is in favour of a systemic mechanism in the acute complications of atherosclerosis...
  10. ncbi A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone
    K Tomokiyo
    The Chemo Sero Therapeutic Research Institute, Kaketsuken, Okubo, Kumamoto, Japan
    Vox Sang 85:290-9. 2003
    ....
  11. ncbi Quantitation of seminal factor IX and factor IXa in fertile, nonfertile, and vasectomy subjects: a step closer toward identifying a functional clotting system in human semen
    Bashir A Lwaleed
    Department of Urology, Central Block, Level E, West Wing, Mail point 67, Southampton University Hospitals NHS Trust, Southampton, Tremona Road, SO16 6YD, United Kingdom
    J Androl 26:146-52. 2005
    ..Congenital defects of FIX synthesis or function cause hemophilia B (originally called hemophilia C)...
  12. ncbi Potential role of recombinant factor VIIa as a hemostatic agent
    Ulla Hedner
    University of Lund, Sweden
    Clin Adv Hematol Oncol 1:112-9. 2003
    ..rFVIIa has also been successfully used in acute trauma patients with profuse bleedings and in other bleeding situations...
  13. ncbi Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia
    S Bjorkman
    Hospital Pharmacy and Department for Coagulation Disorders, Malmo University Hospital, Sweden
    Clin Pharmacokinet 40:815-32. 2001
    ..X-chromosome mutation causes a deficiency of either coagulation factor VIII (FVIII) in haemophilia A, or factor IX (FIX) in haemophilia B...
  14. ncbi Detailed characterization of an anti-factor IX monoclonal antibody that neutralizes the prolonged ox brain prothrombin time of hemophilia B(M) by synthetic peptides
    I Takahashi
    Japanese Red Cross Aichi Blood Center, 539 3 Minamiyamaguchi, Seto, 489 8555, Aichi, Japan
    Peptides 21:603-8. 2000
    In a previous study, we prepared a monoclonal antibody (MoAb) to coagulation factor IX (FIX), designated 65-10, which interfered with the activation of FIX by the activated factor XI/Ca(2+) and neutralized the prolonged ox brain ..
  15. ncbi Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates
    D A Roth
    Center for Hemostasis and Thrombosis Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Blood 98:3600-6. 2001
    ..Despite a lower recovery compared with pdFIX, rFIX controlled hemorrhage in a wide variety of settings and may provide a safety advantage in terms of risk from blood-borne pathogens...
  16. ncbi Cryoprecipitate-removed plasma 'cryo-removed plasma' as a source of factor IX in the treatment of haemophilia B
    L M P Lepatan
    Section of Pediatric Hematology Oncology, University of Santo Tomas Hospital, Manila, Philippines
    Haemophilia 10:254-8. 2004
    Fresh frozen plasma (FFP) is the main source of factor IX (FIX) in the treatment of bleeding episodes of haemophilia B in the Philippines...
  17. ncbi Continuous intravenous infusion of a plasma-derived factor IX concentrate (Mononine) in haemophilia B
    W K Hoots
    University of Texas, Houston Health Science Center, Houston, TX 77030, USA
    Haemophilia 9:164-72. 2003
    ..spontaneous haemorrhage) were enrolled to receive a therapeutic bolus dose followed by CIV infusion of factor IX (FIX) to maintain FIX:C plasma levels of 0.4-1.0 IU mL(-1) (i.e. 40-100%). A median intravenous bolus dose of 54...
  18. ncbi Encapsulated human primary myoblasts deliver functional hFIX in hemophilic mice
    Jianping Wen
    Research and Development, Canadian Blood Services, McMaster University, Hamilton, Ontario, L8N 3Z5 Canada
    J Gene Med 9:1002-10. 2007
    Hemophilia B is a bleeding disorder caused by defective factor IX (FIX), currently treated by regular infusions of plasma-derived or recombinant FIX...
  19. ncbi Variability in bleeding phenotype in Amish carriers of haemophilia B with the 31008 C-->T mutation
    A Sharathkumar
    Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA
    Haemophilia 15:91-100. 2009
    ..to characterize the variability of bleeding phenotype and its association with plasma factor IX coagulant activity (FIX:C) in haemophilia B carriers in a large Amish pedigree with a unifying genetic mutation, C-to-T transition at base ..
  20. ncbi Efficient induction of immune tolerance to coagulation factor IX following direct intramuscular gene transfer
    E F Cohn
    Division of Hematology Oncology, Department of Medicine, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    J Thromb Haemost 5:1227-36. 2007
    The formation of inhibitory anti-factor IX (anti-FIX) antibodies is a major complication of FIX protein replacement-based treatment for hemophilia B. It is difficult to treat patients with anti-FIX antibodies...
  21. ncbi [Double mutation, a 2-bp deletion and Val211Ile, in the blood coagulation factor IX gene of a patient with severe hemophilia B]
    Ikuo Seita
    Department of Molecular Genetics of Coagulation Disorders, Tokyo Medical University, Shinjuku ku, Tokyo 160 0023, Japan
    Rinsho Byori 57:417-24. 2009
    Hemophilia B is an X-linked bleeding disorder caused by the absence or reduced activity of coagulation factor IX (FIX). Here, we report a double mutation in the FIX gene (F9) in a Japanese patient with severe hemophilia B...
  22. ncbi The use of rituximab as an adjuvant for immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate
    Ampaiwan Chuansumrit
    Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
    Blood Coagul Fibrinolysis 19:208-11. 2008
    ..4 to 10 BU. No proteinuria or alteration of renal function was found. In conclusion, rituximab is a helpful adjuvant to immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate...
  23. ncbi Structural analysis of factor IX protein variants to predict functional aberration causing haemophilia B
    S Mukherjee
    Molecular and Human Genetics Division, Indian Institute of Chemical Biology, Council of Scientific and Industrial Research, Kolkata, India
    Haemophilia 14:1076-81. 2008
    Factor IX (FIX) is a component protein of blood coagulation pathway, which activates factor X through interaction with factor VIII and Ca(2+)...
  24. ncbi Use of recombinant factor IX and thromboelastography in a patient with hemophilia B undergoing liver transplantation: a case report
    L De Pietri
    Division of Anesthesiology, University of Modena and Reggio Emilia, Modena, Italy
    Transplant Proc 40:2077-9. 2008
    Hemophilia B is a congenital recessive disorder caused by deficiency of coagulation factor IX (FIX)...
  25. ncbi Prolonged activity of factor IX as a monomeric Fc fusion protein
    Robert T Peters
    Molecular and Cell Biology, Biogen Idec Hemophilia, 9 Fourth Ave, Waltham, MA 02451, USA
    Blood 115:2057-64. 2010
    Treatment of hemophilia B requires frequent infusions of factor IX (FIX) to prophylax against bleeding episodes. Hemophilia B management would benefit from a FIX protein with an extended half-life...
  26. ncbi Liposome-encapsulated DNA-mediated gene transfer and synthesis of human factor IX in mice
    M Baru
    Octa Medical Research Institute, Kiryat Weizmann, Rehovot, Israel
    Gene 161:143-50. 1995
    ..an X-chromosome-linked recessive disorder that is caused by a deficiency of biologically active clotting factor IX (FIX)...
  27. ncbi Creation of a mouse expressing defective human factor IX
    Da Yun Jin
    Gene Therapy Center, Department of Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Blood 104:1733-9. 2004
    ..The mouse expresses no mouse factor IX, but instead expresses a missense mutant human factor IX from the mouse FIX promoter...
  28. ncbi Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B
    J A Aznar
    Hospital Universitario La Fe, Unidad de Coagulopatías Congénitas, Valencia, Spain
    Haemophilia 15:1243-8. 2009
    ..replacement treatment in haemophilia B patients requires a good understanding of the pharmacokinetics of factor IX (FIX)...
  29. ncbi AAV-mediated gene transfer for hemophilia
    K A High
    Department of Pediatrics, University of Pennsylvania School of Medicine, The Children s Hospital of Philadelphia, 19104, USA
    Ann N Y Acad Sci 953:64-74. 2001
    ..The goal of dose escalation is to find a dose that is nontoxic but that results in circulating levels of factor IX >1% in all patients...
  30. ncbi Influence of factor IX on overall plasma coagulability and fibrinolytic potential as measured by global assay: monitoring in haemophilia B
    N A Goldenberg
    Center for Cancer and Blood Disorders, Department of Pediatrics, University of Colorado at Denver and Health Sciences Center The Children s Hospital, Aurora, CO, USA
    Haemophilia 14:68-77. 2008
    We sought to determine the influence of factor IX (FIX) deficiency upon overall coagulative and fibrinolytic capacities in plasma using the clot formation and lysis (CloFAL) assay, and to investigate the role of this global assay as an ..
  31. ncbi Genetic fusion to albumin improves the pharmacokinetic properties of factor IX
    Hubert J Metzner
    CSL Behring GmbH, Emil von Behring Str 76, 35041 Marburg, Germany
    Thromb Haemost 102:634-44. 2009
    ..B is a X-chromosome linked disease characterised by a deficiency of functionally active coagulation Factor IX (FIX)...
  32. ncbi Bioengineered factor IX molecules with increased catalytic activity improve the therapeutic index of gene therapy vectors for hemophilia B
    Nicola Brunetti-Pierri
    Department of Human and Molecular Genetics, Baylor College of Medicine, Houston, TX 77030 77030, USA
    Hum Gene Ther 20:479-85. 2009
    ..Thus, we evaluated the use of three bioengineered factor IX (FIX) variants with improved catalytic activity in the context of the helper-dependent adenoviral vector...
  33. ncbi FIX-Triple, a gain-of-function factor IX variant, improves haemostasis in mouse models without increased risk of thrombosis
    Chung Yang Kao
    Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan
    Thromb Haemost 104:355-65. 2010
    Engineered recombinant factor IX (FIX) with augmented clotting activity may prove useful for replacement therapy, but it has not been studied for risk of thrombosis...
  34. ncbi Factor IX ectopically expressed in platelets can be stored in alpha-granules and corrects the phenotype of hemophilia B mice
    Guowei Zhang
    Department of Pediatrics, Medical College of Wisconsin, Milwaukee, USA
    Blood 116:1235-43. 2010
    We developed 2bF9 transgenic mice in a hemophilia B mouse model with the expression of human factor IX (FIX) under control of the platelet-specific integrin alphaIIb promoter, to determine whether ectopically expressing FIX in ..
  35. ncbi Prophylaxis in factor IX deficiency product and patient variation
    C T Kisker
    University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA
    Haemophilia 9:279-84. 2003
    To determine the dosing needed to maintain a prophylactic level of factor IX (FIX) >/=2%, 15 non-inhibitor severe (</=1% FIX) deficient subjects participated in a double-blind, two-period crossover study to assess the pharmacokinetics ..
  36. ncbi Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis
    S Bjorkman
    Hospital Pharmacy, Malmo University Hospital, Malmo, Sweden
    Haemophilia 7:133-9. 2001
    ..this study were to investigate possible age-related changes in the disposition of factor IX procoagulant activity (FIX:C) after administration of recombinant factor IX (rFIX) and to translate the pharmacokinetic findings into ..
  37. ncbi In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting
    S Bjorkman
    Hospital Pharmacy, Malmo University Hospital, Malmo, Sweden
    Haemophilia 13:2-8. 2007
    ..It has also been suggested that dosing of factor VIII (FVIII) and factor IX (FIX) can be adjusted according to the need of the individual patient, based on an individually determined IVR value...
  38. ncbi Transgene expression levels and kinetics determine risk of humoral immune response modeled in factor IX knockout and missense mutant mice
    T P Zhang
    The Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7220, USA
    Gene Ther 14:429-40. 2007
    ..Although most hemophilia B patients have circulating non-functional but immunologically crossreactive factor IX (FIX) protein (CRM+ phenotype), inciting factors for FIX neutralizing antibody (inhibitor) development have been studied ..
  39. ncbi Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits
    William P Sheffield
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    Br J Haematol 126:565-73. 2004
    Individuals with haemophilia B require replacement therapy with recombinant or plasma-derived coagulation factor IX (fIX). More benefit per injected dose might be obtained if fIX clearance could be slowed...
  40. ncbi Therapeutic plasma concentrations of human factor IX in mice after gene delivery into the amniotic cavity: a model for the prenatal treatment of haemophilia B
    H Schneider
    Division of Biomedical Sciences, Imperial College School of Medicine, London, UK
    J Gene Med 1:424-32. 1999
    ..Based on these studies we hypothesised that the large surface of the fetal skin may be exploitable for high level production of systemically required gene products to be released into the fetal circulation...
  41. ncbi Age-specific regulation of clotting factor IX gene expression in normal and transgenic mice
    E J Boland
    Department of Cellular and Structural Biology, University of Texas Health Science Center at San Antonio 78284 7762, USA
    Blood 86:2198-205. 1995
    Factor IX (FIX), a circulating serine protease that serves as an essential component of the blood coagulation pathway, has been shown to increase with age in humans...
  42. ncbi Activation of blood coagulation factor IX by gingipains R, arginine-specific cysteine proteinases from Porphyromonas gingivalis
    T Imamura
    Division of Molecular Pathology, Department of Neuroscience and Immunology, Kumamoto University Graduate School of Medical Sciences, 2 2 1 Honjo, Kumamoto 860 0811, Japan
    Biochem J 353:325-31. 2001
    ....
  43. ncbi In vivo response to vascular injury in the absence of factor IX: examination in factor IX knockout mice
    Tong Gui
    Department of Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    Thromb Res 121:225-34. 2007
    ..In vivo modeling is possible because of the generation of factor IX(-/-) mice...
  44. ncbi Substitution of the Gla domain in factor X with that of protein C impairs its interaction with factor VIIa/tissue factor: lack of comparable effect by similar substitution in factor IX
    Matthew Ndonwi
    Department of Pharmacological and Physiological Sciences, Saint Louis University School of Medicine, Saint Louis, Missouri 63104, USA
    J Biol Chem 282:15632-44. 2007
    We previously reported that the first epidermal growth factor-like (EGF1) domain in factor X (FX) or factor IX (FIX) plays an important role in the factor VIIa/tissue factor (FVIIa/TF)-induced coagulation...
  45. ncbi Activation of factor IX zymogen results in exposure of a binding site for low-density lipoprotein receptor-related protein
    J G Neels
    Department of Biochemistry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Blood 96:3459-65. 2000
    ..In conclusion, the data presented here indicate that both LRP and proteoglycans have the potential to contribute to the catabolism of factor IXa...
  46. ncbi [Interventional radiology in the palliative treatment of pancreatic cancer]
    E Mazza
    Dipartimento di Fisiopatologia Clinica, , Italia
    Tumori 85:S54-9. 1999
    ..In 44 patients Wallstents were placed during a single PTC session time ("one step" technique). In 21 cases (11%) peri-procedural complications occurred...
  47. ncbi Inactivation and clearance of viruses during the manufacture of high purity factor IX
    A Johnston
    Research and Development, CSL Limited, Bioplasma Division, 189 209 Camp Road, Broadmeadows, Victoria, 3047, Australia
    Biologicals 28:129-36. 2000
    ..Overall, these studies indicate that MonoFIX-VF is a product with an extremely high level of viral safety...
  48. ncbi Collaborative study for the establishment of replacement batches for human coagulation factor IX concentrate reference standards
    E Gray
    National Institute for Biological Standards and Control, Potters Bar, Herts, UK
    Pharmeuropa Bio 2008:19-30. 2008
    ....
  49. ncbi O-Acetylserine sulfhydrylase from Methanosarcina thermophila
    B Borup
    Department of Chemistry, Pennsylvania State University, University Park, PA 16802, USA
    J Bacteriol 182:45-50. 2000
    ..pathways for cysteine biosynthesis have been established for both of these domains, it is unknown how the Archaea fix sulfur or synthesize cysteine...
  50. ncbi Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX
    Junjiang Sun
    Gene Therapy Center, School of Medicine, University of North Carolina at Chapel Hill, NC 27599 7220, USA
    Blood 112:4532-41. 2008
    ..Factor IX knockout (FIX(-/-)) mice received a puncture of the knee joint capsule with a needle to induce hemarthrosis; human factor IX (..
  51. ncbi Direct sequencing of the activation peptide and the catalytic domain of the factor IX gene in six species
    G Sarkar
    Department of Biochemistry and Molecular Biology, Mayo Clinic Foundation, Rochester, Minnesota 55905
    Genomics 6:133-43. 1990
    ....
  52. ncbi Assessment of activated partial thromboplastin time and factor IX in subjects attending an anticoagulation clinic
    C Legnani
    Department of Angiology and Blood Coagulation, University Hospital S Orsola, Bologna, Italy
    Blood Coagul Fibrinolysis 11:537-42. 2000
    Very low factor IX (FIX) levels in patients during oral anticoagulant (OA) treatment, due to mutations in the FIX gene, with prolonged activated partial thromboplastin time (aPTT) and associated with bleeding complications have recently ..
  53. ncbi No impact of factor IX Ala-10 mutations in acenocoumarol-treated southern Europeans
    Dolors Tassies
    Hemotherapy and Hemostasis Department, Hospital Clinic and Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Universitat de Barcelona, Spain
    Blood Coagul Fibrinolysis 16:563-6. 2005
    ..None of the 24 patients carried mutations at Ala-10. Mutations at Ala-10 in factor IX were non-existent in the southern-European population analyzed, and thus, do not represent a relevant cause of bleeding during OA treatment...
  54. ncbi Immune response after neonatal transfer of a human factor IX-expressing retroviral vector in dogs, cats, and mice
    Lingfei Xu
    Department of Internal Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Thromb Res 120:269-80. 2007
    ..However, antibodies could inhibit coagulation, while cytotoxic T lymphocytes could destroy modified cells. The immaturity of the newborn immune system might prevent these immune responses from occurring after neonatal gene therapy...
  55. ncbi Temperature, eluent flow-rate and column effects on the retention and quantitation properties of phenylthiocarbamyl derivatives of amino acids in reversed-phase high-performance liquid chromatography
    A Vasanits
    Institute of Inorganic and Analytical Chemistry, , Budapest, Hungary
    J Chromatogr A 832:109-22. 1999
    The separation and identification possibilities of 27 PTC-amino acids (with particular attention to those present in apples in free forms), are reported on seven RP columns such as, Nucleosil, 3 and 5 microns: 150(+20 guard) x 4...
  56. ncbi Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study
    Man Chiu Poon
    University of Calgary, Alberta, Canada
    Thromb Haemost 87:431-5. 2002
    ..77, median 0.72, range 0.36-1.85, 95% CI of mean 0.74-0.81, expressed as FIX activity increase in U/dL per IU FIX concentrate/kg body weight infused) was significantly lower than that ..
  57. ncbi Macromolecular substrate-binding exosites on both the heavy and light chains of factor XIa mediate the formation of the Michaelis complex required for factor IX-activation
    Dipali Sinha
    Sol Sherry Thrombosis Research Center, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA
    Biochemistry 46:9830-9. 2007
    Binding of factor IX (FIX) to an exosite on the heavy chain of factor XIa (FXIa) is essential for the optimal activation of FIX (Sinha, D., Seaman, F. S., and Walsh, P. N. (1987) Biochemistry 26, 3768-3775)...
  58. ncbi Neutrophil elastase cleavage of human factor IX generates an activated factor IX-like product devoid of coagulant function
    J A Samis
    Department of Pathology, Queen s University, Kingston, Ontario, Canada
    Blood 92:1287-96. 1998
    ..These in vitro observations support the possibility that increased HNE cleavage of F.IX in vivo may contribute to the disregulation of hemostasis that occurs in conditions such as disseminated intravascular coagulation (DIC)...
  59. ncbi Carboxylase overexpression effects full carboxylation but poor release and secretion of factor IX: implications for the release of vitamin K-dependent proteins
    Kevin W Hallgren
    Department of Molecular Cardiology, Lerner Research Institute, Cleveland, Ohio 44195, USA
    Biochemistry 41:15045-55. 2002
    ..We analyzed carboxylation in 293- and BHK cell lines expressing r-factor IX (fIX) and endogenous carboxylase or overexpressed r-carboxylase...
  60. ncbi Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans
    Fung Sing Chow
    Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, PA, USA
    Clin Pharmacol Ther 71:235-45. 2002
    ..SB 249417 is a humanized anti-factor IX/IXa antibody that, on administration to rats and monkeys, produces an immediate suppression of factor IX activity and prolongation of activated partial thromboplastin times (aPTT)...
  61. ncbi Identification of residues in the Gla-domain of human factor IX involved in the binding to conformation specific antibodies
    E G Wojcik
    Haemostasis and Thrombosis Research Centre, University Hospital Leiden, The Netherlands
    Biochim Biophys Acta 1382:91-101. 1998
    ..Anti-FIX:Mg(II) antibodies recognize a conformational epitope (FIX') that can be induced by several metal ions such as Ca2+, ..
  62. ncbi Age and sex dependent regulation of the factor IX gene in mice
    S Kurachi
    Department of Human Genetics, University of Michigan Medical School, Ann Arbor 48109 0618, USA
    Thromb Haemost 76:965-9. 1996
    ..In mice, both factor IX activity and mRNA levels are significantly higher in males than in females, which has not been described for humans...
  63. ncbi Effect of Ca2+ and Mg2+ concentration in culture medium on the activation of recombinant factor IX produced in Chinese hamster ovary cells
    Won Hee Kim
    Department of Biological Sciences, KAIST, 335 Gwahangno, Yuseong Gu, Daejeon 305 701, Republic of Korea
    J Biotechnol 142:275-8. 2009
    Factor IX (FIX) plays an important role in the blood coagulation cascade. When Chinese hamster ovary (CHO) cells producing recombinant human FIX were cultivated using a serum-free medium (SFM) containing 1.12 mM of Ca(2+) and 0...
  64. ncbi Identification and functional characterization of a polymorphic oestrogen response element in the human coagulation factor IX gene promoter
    B Adams
    Academic Unit of Haematology, Division of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK
    Br J Haematol 140:241-9. 2008
    The liver expressed procoagulant factor IX (FIX) shows inter-individual variation in levels, some of which is heritable. Raised levels of FIX are associated with a thrombotic tendency...
  65. ncbi Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective
    S Bjorkman
    Hospital Pharmacy, Malmo University Hospital, Sweden
    Haemophilia 9:101-8; discussion 109-10. 2003
    The high cost and limited availability of factor concentrates make dosing of factor VIII (FVIII) or factor IX (FIX) a crucial issue in the prophylactic treatment of haemophilia...
  66. ncbi Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate
    A Ruiz-Saez
    Centro Nacional de Hemofilia, Banco Municipal de Sangre del Distrito Capital, Caracas, Venezuela
    Haemophilia 11:583-8. 2005
    ..and safety of two plasma-derived double-inactivated (solvent/detergent heating at 100 degrees C, 30 min) factor IX (FIX) concentrates, UMAN COMPLEX DI (product A) [plasma-derived prothrombin concentrates (PCC)] and a high purity FIX ..
  67. ncbi Evaluation of a physician education intervention to improve primary care for low-back pain. I. Impact on physicians
    D Cherkin
    Center for Health Studies, Seattle Veterans Affairs Medical Center, Washington
    Spine (Phila Pa 1976) 16:1168-72. 1991
    ..of negative feelings about patients with back pain or frustration with patients who wanted their doctor to "fix" their problem...
  68. ncbi [Acute disseminated encephalomyelitis in a 3-month-old infant]
    T Taketani
    Department of Pediatrics, Shimane Medical University, Izumo, Shimane
    No To Hattatsu 33:172-7. 2001
    ..When she was admitted three days after the onset, she could neither fix or follow objects with her eyes nor respond to sound. Her muscle tone was decreased...
  69. ncbi Secondary hyperparathyroidism: evidence for an association with papillary thyroid cancer
    M L Klyachkin
    Department of Surgery, University of Kentucky Medical Center, Lexington 40536-0084, USA
    Am Surg 67:397-9. 2001
    ..We report three patients in whom invasive papillary thyroid carcinoma (PTC) was diagnosed before (one case) or at the time of (two cases) parathyroidectomy for SHPT...
  70. ncbi Nicotine on the revascularization of bone graft. An experimental study in rabbits
    T K Daftari
    Department of Orthopaedics, Emory University, Decatur, Georgia
    Spine (Phila Pa 1976) 19:904-11. 1994
    ..Serum levels of nicotine were measured weekly. Colored silicone was injected at sacrifice to fix the vasculature of the bone graft. Histologic analysis of undecalcified sections was performed. RESULTS...
  71. ncbi Hypertension: where have we gone wrong and how can we fix it?
    J M Neutel
    Orange County Heart Institute and Research Center, Orange, California 92868, USA
    Am J Hypertens 11:150S-157S. 1998
    ..To improve our management, we need to find methods to diagnose these patients early in the course of this disease process, and to treat it as a syndrome rather than as a number...
  72. ncbi Electro-oculogram in multiple system and late onset cerebellar atrophies
    J Arpa
    Servicio de Neurologia, Hospital La Paz, Madrid
    Rev Neurol 23:969-74. 1995
    ..Cerebellar signs were significantly correlated with impaired VOR-fix gain and OKN, abnormalities of saccades, and reduced smooth pursuit gain (p < 0.05)...
  73. ncbi Biomechanical evaluation of translaminar facet joint fixation. A comparative study of poly-L-lactide pins, screws, and pedicle fixation
    M Deguchi
    Department of Orthopedic Surgery, Nagano Red Cross Hospital, Japan
    Spine (Phila Pa 1976) 23:1307-12; discussion 1313. 1998
    ..CONCLUSIONS: The facet joint is the only true articulation in the lumbosacral spine. It is logical to fix this part directly to achieve spine fixation...
  74. ncbi Determination of amino acids in the foods by reversed-phase high-performance liquid chromatography with a new precolumn derivative, butylthiocarbamyl amino acid, compared to the conventional phenylthiocarbamyl derivatives and ion-exchange chromatography
    K L Woo
    Department of Food Engineering, Kyungnam University, Masan, South Korea
    J Chromatogr A 740:31-40. 1996
    ..The sensitivity of BTC-amino acid was similar to phenylthiocarbamyl (PTC) amino acid. The detection limit in both derivatives was about 3.9 pmol at 0...
  75. ncbi A combination of chemical derivatisation and improved bioinformatic tools optimises protein identification for proteomics
    F L Brancia
    Michael Barber Centre for Mass Spectrometry, UMIST, Manchester, UK
    Electrophoresis 22:552-9. 2001
    ..Second, an Edman-type phenylthiocarbamoyl (PTC) modification is carried out on the N-terminal amino acid...
  76. ncbi Liquid crystalline polymers as stationary phases. IV. Chemical bonding and immobilization of the polymer on silica characterization by solid-state nuclear magnetic resonance spectroscopy
    F Gritti
    ENSCPB, , Pessac Talence, France
    J Chromatogr A 922:37-50. 2001
    Chemical bonding reaction and immobilization through low energy radiation (heating) have been investigated to fix a side-chain liquid crystalline polymer (SC-LCP) on silica particles in order to use the resulting modified silica in ..
  77. ncbi A biomechanical study of a cervical spine stabilization device: Roy-Camille plates
    M E Smith
    Department of Mechanical and Aerospace Engineering, Rutgers The State University of New Jersey, Piscataway, USA
    Spine (Phila Pa 1976) 22:38-43. 1997
    STUDY DESIGN: Three-hole Roy-Camille posterior plates (Howmedica, Inc., Rutherford, NJ) were used to fix severely destabilized fresh cadaveric cervical spines...
  78. ncbi Vascularization of the fusion mass in a posterolateral intertransverse process fusion
    Y Toribatake
    Department of Orthopaedic Surgery, School of Medicine, Kanazawa University, Japan
    Spine (Phila Pa 1976) 23:1149-54. 1998
    ..The rabbits were killed at 3 weeks (n = 6) and 6 weeks (n = 25) after surgery, and colored silicone was injected to fix the vasculature...
  79. ncbi Sensitive assay to detect thyroid stimulating antibody (TSAb) in the presence of thyroid stimulation blocking antibody (TSBAb) in serum
    Y Ochi
    Research Institute for Production Development, Sakyo, Kyoto, Japan
    Horm Metab Res 33:115-20. 2001
    ..We recently demonstrated that polyethylene glycol (PEG) augments TSAb activity in porcine thyroid cells (PTC) assay...
  80. ncbi Size-exclusion chromatography of plasma proteins with high molecular masses
    D Josic
    Octapharma Produktionsges m b H, Wien, Austria
    J Chromatogr A 796:289-98. 1998
    ..The model mixtures are preparations of the clotting factors VIII (FVIII) and IX (FIX)...
  81. ncbi [Mechanisms of platelet activation and development of antiplatelet agents]
    J P Cazenave
    INSERM U 311, Strasbourg
    Arch Mal Coeur Vaiss 89:1501-6. 1996
    ..main families: antagonists of the membrane receptors of activation coupled to signal transducting G proteins which fix circulating stimuli such as ADP, thrombin and TXA2 and inhibitors of the binding of adhesive proteins such as ..
  82. ncbi A biomechanical investigation of short segment spinal fixation for burst fractures with varying degrees of posterior disruption
    K A Mann
    Department of Orthopedic Surgery, SUNY Health Science Center Syracuse
    Spine (Phila Pa 1976) 15:470-8. 1990
    ..that both systems reduce spinal flexibility in flexion, extension, and lateral bend loading when used to reduce and fix a classic burst fracture without posterior disruption...
  83. ncbi Treatment of infected clench-fist human bite wounds in the area of metacarpophalangeal joints
    A P Chadaev
    Department of General Surgery, Russian State Medical University, Moscow, Russia
    J Hand Surg Am 21:299-303. 1996
    ..bone destruction (89 patients) was treated the same way as group 2 with the addition of a distraction device to fix and "unload" the joint...
  84. ncbi Total thyroidectomy is the recommended treatment for all Papillary Thyroid Carcinoma (PTC)
    J Santini
    Dept. of Otolaryngology, Head and Neck Surgery, C.H.U. Pasteur, Nice, France
    Acta Otorhinolaryngol Belg 53:161-4. 1999
    ..The major unresolved debate concerning the ideal surgical management of PTC focuses on the extent of thyroidectomy...
  85. ncbi Percutaneous pinning of distal radius fractures: a biomechanical study
    S H Naidu
    Department of Orthopaedic Surgery and Rehabilitation, Pennsylvania State University, Hershey, USA
    J Hand Surg Am 22:252-7. 1997
    ..5 cm proximal to the radial styloid. Three pin sizes and four pin configurations were used to fix the fracture, and the constructs were mechanically tested. Results show that at least a ...
  86. ncbi The biomechanical effect and clinical application of a Ni-Ti shape memory expansion clamp
    F Mei
    Department of Orthopedics, Xinqiao Hospital, Third Military Medical University, Chongqing, China
    Spine (Phila Pa 1976) 22:2083-8. 1997
    ..The shape memory expansion clamp had been used to fix rotated circular grafts in 30 cases with cervical spine injuries or cervical spondylosis after anterior ..
  87. ncbi Bioactive bone cements
    E J Harper
    Interdisciplinary Research Centre in Biomedical Materials, Queen Mary and Westfield College, University of London
    Proc Inst Mech Eng H 212:113-20. 1998
    Poly(methylmethacrylate) (PMMA) bone cement, used to fix implants into the bone, produces good surgical results if used correctly...
  88. ncbi Osseointegrated finger prosthesis: An alternative method for finger reconstruction
    P Manurangsee
    Division of Plastic Surgery, Lerdsin General Hospital, Bangkok, Thailand
    J Hand Surg Am 25:86-92. 2000
    ..A 2-stage reconstruction procedure with osseointegrated titanium implants was performed in each patient to fix a finger prosthesis to the proximal phalanx...
  89. ncbi Forearm fracture plates: to remove or not to remove
    D A Labosky
    Department of Orthopedic Surgery, West Virginia University, Morgantown 26506
    J Hand Surg Am 15:294-301. 1990
    Eighty dynamic compression plates used to fix fractures of the radius and/or ulna were removed from 51 of 98 adult patients. Thirty-seven patients had plates removed electively. Fourteen patients had plates removed for clinical reasons...
  90. ncbi Preparation of various silica-based columns for capillary electrochromatography by in-column derivatization
    S Suzuki
    Faculty of Pharmaceutical Sciences, Kinki University, Higashi-Osaka, Japan
    J Chromatogr A 873:247-56. 2000
    ..Since the presence of frit filters hampers high efficiency separation, an attempt was made to fix the bed of modified silica gel particles to the capillary inner wall by a cross-linking technique...
  91. ncbi Effect of spinal construct stiffness on early fusion mass incorporation. Experimental study
    C E Johnston
    Texas Scottish Rite Hospital, Dallas
    Spine (Phila Pa 1976) 15:908-12. 1990
    ..stiffer fusions in axial testing, due to a technical limitation of the button-wire implants used to segmentally fix the rods at each vertebra...
  92. ncbi Modified technique of tension band wiring in flexion injuries of the middle and lower cervical spine
    M O al Baz
    Department of Trauma and Orthopaedic Surgery, King Fahd Hospital, Jeddah, Saudi Arabia
    Spine (Phila Pa 1976) 20:1241-4. 1995
    ..SUMMARY AND BACKGROUND DATA. The prevalent surgical techniques of Segal et al and Davey et al fix unstable injuries of the cervical spine by passing two transverse "K" wires through the skin and the spinous ..
  93. ncbi Augmented external fixation of unstable distal radius fractures
    W H Seitz
    Department of Orthopaedic Surgery, Mt Sinai Medical Center, Cleveland, OH 44106
    J Hand Surg Am 16:1010-6. 1991
    ..the use of percutaneous Kirschner wires to secure the radial styloid fragment as a lateral buttress, elevate and fix in place the depressed lunate fossa fragment, and, when necessary, add support to the elevated articular surface by ..
  94. ncbi The accessory root of the medial fascicle of the brachial plexus in man
    Z Urbanowicz
    , Akademia Medyczna w Lublinie
    Ann Univ Mariae Curie Sklodowska Med 50:9-12. 1995
    ..The methods used to visualize different structures of brachial plexus, to obtain and fix the sections, to stain the slides and to determine thickness of the examined parts of peripheral nervous system, ..
  95. ncbi Palmar lunate trans-scaphoid, trans-triquetral fracture-dislocation
    P Harrington
    St Vincent s Hospital, Dublin, Ireland
    J Hand Surg Br 24:493-6. 1999
    ..A second operation was required to internally fix the displaced triquetral fracture and reduce the lunotriquetral dissociation...
  96. ncbi Temporal trends and clinical correlates for the ret/PTC1 mutation in papillary thyroid carcinoma
    John R Burgess
    Department of Diabetes and Endocrine Services, Royal Hobart Hospital, GPO Box 1061L, Hobart, Tasmania 7001, Australia
    ANZ J Surg 73:31-5. 2003
    The incidence of papillary thyroid carcinoma (PTC) has increased in Australia at a rate exceeding 10% per annum over the past two decades. In Tasmania the increase has averaged 24% per year between 1982 and 1997...
  97. ncbi New insight into the transcarbamylase family: the structure of putrescine transcarbamylase, a key catalyst for fermentative utilization of agmatine
    Luis Mariano Polo
    Instituto de Biomedicina de Valencia and Centro de Investigación Biomédica en Red de Enfermedades Raras, Valencia, Spain
    PLoS ONE 7:e31528. 2012
    ..and ornithine transcarbamylase (OTC) are well characterized, little was known about putrescine transcarbamylase (PTC), the enzyme that generates CP for ATP production in the fermentative catabolism of agmatine...
  98. ncbi c-Met inhibitor synergizes with tumor necrosis factor-related apoptosis-induced ligand to induce papillary thyroid carcinoma cell death
    Rong Bu
    Human Cancer Genomic Research, Research Center, Riyadh, Saudi Arabia
    Mol Med 18:167-77. 2012
    ..Previously we have shown that c-Met is overexpressed in Middle Eastern papillary thyroid carcinoma (PTC) and significantly associated with an aggressive phenotype, but its role has not been fully elucidated in PTC...
  99. ncbi Analysis of the N-glycans of recombinant human Factor IX purified from transgenic pig milk
    Geun Cheol Gil
    Department of Chemical and Biomolecular Engineering, University of Nebraska Lincoln, Lincoln, NE 68588, USA
    Glycobiology 18:526-39. 2008
    ..In this work, the N-glycan structures of recombinant human Factor IX (tg-FIX) produced in the transgenic pig mammary gland were determined...
  100. ncbi Nodule heterogeneity as shown by size differences between the targeted nodule and the tumor in thyroidectomy specimen: a cause for a false-negative diagnosis of papillary thyroid carcinoma on fine-needle aspiration
    Masood A Siddiqui
    Department of Pathology, University of Michigan, Ann Arbor, Michigan 48109 0054, USA
    Cancer 114:27-33. 2008
    Missed papillary thyroid carcinoma (PTC) diagnoses on fine-needle aspiration (FNA) can result from many causes...
  101. ncbi Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia
    Boban Stanojevic
    Department of Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1 12 4 Sakamoto, Nagasaki 852 8523, Japan
    Endocr J 58:381-93. 2011
    Molecular pathogenesis of papillary thyroid carcinoma (PTC) is largely associated with mutational changes in the BRAF, RAS family and RET genes...

Research Grants83

  1. Regulation of factor VIII Levels and Activity by Members of LDL Receptor Family
    Dudley Strickland; Fiscal Year: 2009
    Factor VIII (fVIII) and factor IX (fIX) are two key plasma proteins that are deficient in the bleeding disorders Hemophilia A and Hemophilia B, respectively...
  2. Regulation of factor VIII Levels and Activity by Members of LDL Receptor Family
    DUDLEY K contact STRICKLAND; Fiscal Year: 2010
    Factor VIII (fVIII) and factor IX (fIX) are two key plasma proteins that are deficient in the bleeding disorders Hemophilia A and Hemophilia B, respectively...
  3. BIOCHEMISTRY OF VARIANTS OF FACTOR IX
    S Bajaj; Fiscal Year: 1990
    ....
  4. Immunology of Factor IX Gene Transfer to Liver
    Roland W Herzog; Fiscal Year: 2010
    ..Therefore, superior immune tolerance protocols are highly desirable. ..
  5. Immunology of Factor IX Gene Transfer to Liver
    Roland W Herzog; Fiscal Year: 2011
    ..Therefore, superior immune tolerance protocols are highly desirable. ..
  6. Bioencapsulated Factor IX for Oral Tolerance in Hemophilia B
    ROLAND HERZOG; Fiscal Year: 2007
    ..In future studies, the oral tolerance protocol will be further optimized and adapted to prevention of inhibitors to factor VIII in treatment of hemophilia A. ..
  7. GENE THERAPY FOR HEMOPHILIA A AND B
    Inder Verma; Fiscal Year: 2003
    ..Finally, we believe that the knowledge gained from gene therapy of hemophilia will serve as an excellent model system for many genetic diseases. ..
  8. Efficacy and Safety of AAV Gene Transfer for Hemophilia
    VALDER ARRUDA; Fiscal Year: 2004
    ..abstract_text> ..
  9. GENE THERAPY FOR BLOOD PROTEIN DEFICIENCIES
    KATHERINE PONDER; Fiscal Year: 2005
    ..Success in this project might lead to a safe, effective, and permanent therapy for Hemophilia B. ..
  10. Immunology of Factor IX Gene Transfer to Liver
    ROLAND HERZOG; Fiscal Year: 2006
    ..Taken together, these studies will provide a detailed analysis of transgene product-specific T cell responses following AAV-mediated hepatic gene transfer. ..
  11. Clinical trial of self complementary AAV8-mediated gene transfer for hemophilia B
    Andrew M Davidoff; Fiscal Year: 2010
    ..Hemophilia B (HB) is an X-linked recessive bleeding disorder that results from a defect in the factor IX (FIX) gene which encodes a serine protease critical for appropriate fibrin clot formation...
  12. Clinical trial of self complementary AAV8-mediated gene transfer for hemophilia B
    Andrew Davidoff; Fiscal Year: 2009
    ..Hemophilia B (HB) is an X-linked recessive bleeding disorder that results from a defect in the factor IX (FIX) gene which encodes a serine protease critical for appropriate fibrin clot formation...
  13. Factor IX tolerance in hemophilia gene therapy
    Hengjun Chao; Fiscal Year: 2007
    Hemophilia B is an X-linked hemorrhagic disorder due to factor IX (FIX) deficiency...
  14. Gene Therapy for hemophilia using muscle-expressed FVIIa
    Katherine A High; Fiscal Year: 2011
    ..This approach has immunological advantages over Factor IX (FIX) or Factor VIII (FVIII) gene strategies since the recipient is tolerant to the transgene...
  15. BIOCHEMISTRY OF NORMAL & ABNORMAL VARIANTS OF FACTOR IX
    S Bajaj; Fiscal Year: 2001
    ..These studies could also lead to the design of arthitorombotoc reagents and inhibit the TF-induced the TF-induced coagulation. ..
  16. Factor lXa-Factor Vllla complexes in blood coagulation
    Bruce Furie; Fiscal Year: 2007
    ..abstract_text> ..
  17. BIOCHEMISTRY OF NORMAL & ABNORMAL VARIANTS OF FACTOR IX
    S Bajaj; Fiscal Year: 1993
    ..In addition, the studies will define the molecular basis of TFPI deficiency in the patients investigated...